Allergios®
About Allergios®
Allergios® is a healthcare AI company focused on revolutionizing allergy diagnostics. The company has developed a method and system, based on research from the University of Bremen and Medical University of Vienna, that directly diagnoses allergies by visualizing the allergic response. Their solution involves an in-vitro allergy diagnostic that analyzes how patient blood serum induces degranulation of basophil cells in the presence of an allergen. This is achieved using a disposable microfluidic chip, an optical reader called GranulEye®, and AI-based analysis software.
The objective of Allergios® is to provide timely and effective treatment options for clinicians by offering a clear and unambiguous allergy diagnosis. The company initially focuses on food allergies, aiming to replace the traditional food challenge test, and plans to expand to other IgE-mediated allergies. Allergios® received a HealthHolland grant in October 2024 to support a public-private partnership with Wageningen University & Research, validating the GranulEye® test for food allergy diagnosis. Following a strategic reset in Q2 2025, Allergios® is currently focused on transforming their technology prototype into a fully validated diagnostic platform, with a Series A funding round targeted for mid-2026.
Focus Areas
Business Intelligence
| Key Investors | NLC Health Ventures |
| Partnerships | Wageningen University & Research |
| Technology | cloud-native, AI-based image analysis, disposable microfluidic chip, holography reader (GranulEye®) |
What Physicians Need to Know
Allergiosu00ae offers a novel approach to allergy diagnosis, particularly for food allergies, by providing a direct, cell-based blood test that aims to be safer and more efficient than current methods like oral provocation tests. The use of a disposable microfluidic chip, an optical reader (GranulEyeu00ae), and AI-based analysis software allows for timely and effective treatment options based on clear and unambiguous diagnoses. This technology can help allergists and immunologists, as well as primary care physicians, to accurately identify causative allergens and monitor the risk of disease onset. The system is designed for integration into routine laboratory workflows and potentially for point-of-care use, minimizing manual intervention. Physicians can anticipate more reliable results due to the use of purified allergens and the ability to detect IgE reactivity towards a broad array of allergens simultaneously with a small serum volume.
Allergiosu00ae is developing a robust, automatable platform for functional, cell-based allergy diagnostics in routine clinical settings. Their system, consisting of a microfluidic chip, a holography reader, and AI-based software, is designed to streamline the diagnostic process. The current focus is on building a reliable, label-free Basophil Activation Test with minimal manual intervention, aiming for integration into routine laboratory workflows and towards point-of-care applications. This suggests a future where their technology could be integrated into existing lab infrastructure for efficient allergy testing.
Reviews & Opinions
Videos
News, demos, and interviews about Allergios®.
Videos load interactively. If none appear, search YouTube for Allergios® →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]